Institutional members access full text with Ovid®

Share this article on:

An Update in Laser and Pharmaceutical Treatment for Polypoidal Choroidal Vasculopathy

Lai, Timothy Y.Y. MD, FRCS, FRCOphth,*†; Chan, Wai-Man FRCP, FRCOphth*‡

Asia-Pacific Journal of Ophthalmology: March/April 2012 - Volume 1 - Issue 2 - p 97–104
doi: 10.1097/APO.0b013e31823e5a95
Review Article

Abstract: Polypoidal choroidal vasculopathy (PCV) is a condition characterized by multiple, recurrent, serosanguineous pigment epithelium detachment and neurosensory retinal detachment due to abnormal choroidal polypoidal lesions. Polypoidal choroidal vasculopathy is particularly prevalent in Asians and occurs in up to 30% of patients presenting with neovascular age-related macular degeneration. In recent years, various treatment modalities have been described in the literature for the treatment of PCV. This review article aims to provide an overview and to summarize the current nonsurgical treatment for PCV.

From the *Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong; †2010 Retina and Macula Centre, Kowloon; and ‡Department of Ophthalmology, Hong Kong Sanatorium and Hospital, Hong Kong.

Received for publication August 21, 2011; accepted September 5, 2011.

Reprints: Timothy Y.Y. Lai, MD, FRCS, FRCOphth, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, 3/F, Hong Kong Eye Hospital, 147K Argyle St, Kowloon, Hong Kong. E-mail: tyylai@cuhk.edu.hk.

Dr Lai has received honoraria for lecture fees and consultancy from Novartis Inc and Heidelberg Engineering. Dr Chan has no funding or conflicts of interest to declare.

© 2012Asia-Pacific Academy of Ophthalmology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website